DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20211962

A survey on psychological effects following administration of the first dose of COVID-19 (Oxford-AstraZeneca-Covishield) vaccine in Sri Lanka: experience among the medical community

Warnakula Weerasooriya Jayathilaka Sashka Madushi Rowel, Kodithuwakku Arachchilage Sajith Uditha Asanka Kodithuwakku, Jayawardhana Mudiyanselage Pradeepa Sanjeewa

Abstract


Background: Research on psychoimmunology has demonstrated a bidirectional relationship between the immune system and the brain. Although the evidence is conflicting, few studies are suggesting a temporal association between neuropsychiatric disorders and some vaccines. However, research is scarce in this area. We observed that some recipients experienced various transient psychological symptoms in addition to physical symptoms following administration of the first dose of Oxford-AstraZeneca-Covishield vaccine in Sri Lanka. The objective of this survey was to assess the nature, associations and duration of the psychological symptoms observed following the vaccine.

Methods: A cross-sectional online survey was conducted among the medical community in the age range of 25-63 years, who received the first dose of the vaccine. The questionnaire inquired demographic details, physical symptoms, psychological symptoms, duration of symptoms and their view on taking the second dose and recommending it to family or friends.

Results: The majority (94.6%) of the participants had experienced some form of a physical symptom and 85.2% experienced at least one psychological symptom. Those who had fever experienced a higher rate of psychological symptoms compared to those who hadn’t. However, this difference was not significant. The majority developed symptoms after 12 hours of receiving the vaccine and the symptoms lasted for less than 48 hours.

Conclusions: Notable rates of psychological symptoms were observed in recipients of the first dose of Oxford-AstraZeneca-Covishield vaccine. However, these symptoms were self-limiting. Further studies are needed to ascertain if these observations are significant.


Keywords


Oxford-AstraZeneca-Covishield vaccine, Psychological symptoms, Sri Lanka

Full Text:

PDF

References


Arashkia A, Jalilvand S, Mohajel N, Afchangi A, Azadmanesh K, et al. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Rev Med Virol. 2020;e2183.

Watanabe Y, Mendonça L, Allen ER, Howe A, Lee M, Allen JD, et al. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. bioRxiv. 2021;7(4):594-602.

Ader R, Cohen N, Felten D. Psychoneuro-immunology: interactions between the nervous system and the immune system. Lancet. 1995; 345(8942):99-103.

Leckman JF, Vaccarino FM. Editorial commentary: "What does immunology have to do with brain development and neuropsychiatric disorders?". Brain Res. 2015;1617:1-6.

O'Connor TG, Moynihan JA, Wyman PA, Carnahan J, Lofthus G, Quataert SA, et al. Depressive symptoms and immune response to meningococcal conjugate vaccine in early adolescence. Dev Psychopathol. 2014;26(4):1567-76.

Leslie DL, Kobre RA, Richmand BJ, Aktan Guloksuz S, Leckman JF. Temporal association of certain neuropsychiatric disorders following vaccination of children and adolescents: a pilot case-control study. Front Psychiatry. 2017;8:3.

Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry. 2003;60(10):1009-14.

Jang FL, Kao PH. The potential use of using the psychological side effects of antidepressants in treating cancer patients. Taiwan J Psychia. 2019; 33:227-8.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396(10267):1979-93.

Sah R, Shrestha S, Mehta R, Sah SK, Rabaan AA, Dhama K, et al. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal. Travel Med Infect Dis. 2021;40:101989.